Gloveless isolators don’t end interventions. Learn to assess intervention dependency in robotic aseptic filling and when glove ports are justified.
|Articles|September 2, 2001
- Pharmaceutical Technology-09-02-2001
- Volume 25
- Issue 9
Replacing the Animal Component in SerumEvaluating Raw Materials for Inclusion in Optimized Hybridoma Media
With the scarcity of CGMP facilities spurring a production crisis, manufacturers need to optimize their processes and formulations for individual hybridoma cell lines and production systems.
Advertisement
Articles in this issue
about 25 years ago
Six Sigma Can Give Contractors a Quality Advantageabout 25 years ago
Industry Changes OTC Labels as Deadline Approachesabout 25 years ago
A Report of the PQRI Workshop on Blend Uniformityabout 25 years ago
Are You Ready for Global Manufacturing?about 25 years ago
Pharmaceutical Coverage and Costsabout 25 years ago
Outsourcing OutlookAdvertisement
Related to this article
Terry Katz, CEO and co-founder of ForgeStop Technology Corporation, explains how the company’s product is worth the investment by protecting products and patients.
The FDA has shelved its National Priority Voucher pilot, leaving sponsors that built CMC and launch-readiness plans around 1- to 2-month reviews facing uncertain timelines.
Regulators will test pharma companies against their own internal AI policies. Jaenisch, Muraru, and Pandey explain how to build defensible, inspection-ready AI practices.
Terry Katz, CEO and co-founder of ForgeStop Technology Corporation, explains how its connected technology can enhance anticounterfeiting and how data are handled within the product.
Celtic Renewables won the CPHI Award for Sustainable Pharma Excellence for its green chemicals used in pharmaceutical manufacturing. Bettina Brierley, chief commercial officer, talks about the adoption, capacity, and pricing of biosolvents.
Terry Katz, CEO and cofounder of ForgeStop Technology Corporation, explains the company’s CPHI Award-winning connected product technology and how it helps to combat drug counterfeiting.
FDA approved pimicotinib for TGCT based on a 56% response rate; its Project Orbis review signals tighter global launch planning for manufacturers.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Signs Point to FDA Shelving Priority Voucher Pilot, Stalling Fast-Track Drug Reviews
2
$1.15B AI-Guided Macrocycle Discovery Lands at argenx
3
Pimicotinib TGCT Approval Shows How Assessment Aid Supports Review
4
Our Biggest Takeaways From AAPS PharmSci 360
5